DDInter1478 DDInter899
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Piroxicam {u} (Compound) resembles {v} (Compound) Meloxicam
Piroxicam {u} (Compound) binds {v} (Gene) ALB
Piroxicam {u} (Compound) palliates {v} (Disease) osteoarthritis
Piroxicam {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Piroxicam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Famotidine
Piroxicam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Piroxicam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Piroxicam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desmopressin
Piroxicam {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Piroxicam {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Piroxicam (Compound) resembles Meloxicam (Compound)
Piroxicam (Compound) binds ALB (Gene)
Piroxicam (Compound) palliates osteoarthritis (Disease)
Piroxicam (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Piroxicam may cause a minor interaction that can limit clinical effects when taken with Famotidine
Piroxicam may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin
Piroxicam may lead to a major life threatening interaction when taken with Iohexol
Piroxicam may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan